Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,782.81
(
2.51%
)
US TECH 100
24,183.06
(
2.72%
)
Dow Jones
47,909.92
(
2.85%
)
Brent Oil
95.34
(
0.53%
)
Bitcoin
70,887.92
(
-0.34%
)
News Focus
News Focus

Replies to post #414589 on Elite Pharmaceuticals Inc (ELTP)

Replies to #414589 on Elite Pharmaceuticals Inc (ELTP)
icon url

jour_trader

11/14/24 4:44 PM

#414590 RE: BoyWidaDreamOr2 #414589

That is their normal & primary revenue stream. That is pure growth. Very little licensing going forward. 
icon url

kayak_wench

11/14/24 4:54 PM

#414596 RE: BoyWidaDreamOr2 #414589

Compared to year ago, but manufacturing fees were down from last quarter while licensing fees were up.

I’m surprised that we didn’t increase revenue given we launched methotrexate. Price will go down in until we get PR on Vyvanse or for Percocet launch.